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Background. There remains concern regarding the occurrence of noncommunicable diseases (NCDs) among individuals aging 
with human immunodeficiency virus (HIV), but few studies have described whether disparities between demographic subgroups 
are present among individuals on antiretroviral therapy (ART) with access to care.
Methods. We assessed the first documented occurrence of type 2 diabetes mellitus (DM), chronic kidney disease (CKD), and 
treated hypertension (HTN) by age, sex, and race within the North American AIDS Cohort Collaboration on Research and Design 
(NA-ACCORD). HIV-infected adults (≥18 years) who initiated ART were observed for first NCD occurrence between 1 January 
2000 and 31 December 2013. Cumulative incidences as of age 70 were estimated accounting for the competing risk of death; Poisson 
regression was used to compare rates of NCD occurrence by demographic subgroup.
Results. We included >50 000 persons with >250 000 person-years of follow-up. Median follow-up was 4.7 (interquartile range, 2.4–
8.1) years. Rates of first occurrence (per 100 person-years) were 1.2 for DM, 0.6 for CKD, and 2.6 for HTN. Relative to non-black women, 
the cumulative incidences were increased in black women (68% vs 51% for HTN, 52% vs 41% for DM, and 38% vs 35% for CKD; all 
P < .001); this disparity was also found among men (73% vs 60% for HTN, 44% vs 34% for DM, and 30% vs 25% for CKD; all P < .001).
Conclusions. Racial disparities in the occurrence of DM, CKD, and HTN emphasize the need for prevention and treatment 
options for these HIV populations receiving care in North America.
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Human immunodeficiency virus (HIV)–infected individu-
als are living longer due to the use of effective antiretroviral 
therapy (ART) [1]. Principally because of this increased life 
expectancy, it is projected that by the end of 2017, 50% of 
the US population living with HIV/AIDS will be >50  years 
old [2]. This public health success is tempered by concerns 
for long-term health and quality of life. Noncommunicable 
diseases (NCDs) typically associated with aging in the gen-
eral population have emerged as significant sources of clinical 
concern [3].
Type 2 diabetes mellitus (DM), chronic kidney disease 
(CKD), and hypertension (HTN) are important NCDs that 
result in significant morbidity. They have great implications on 
cardiovascular disease, a leading cause of death in those with 
HIV [4], having been identified as risk factors for atheroscle-
rotic heart and other vascular diseases [5, 6]. However, whether 
and to what extent disparities of these NCDs exist in HIV 
patients receiving care is unclear. Prospective data are lacking 
among specific demographic subgroups with HIV previously 
identified as being differentially at risk for age-related diseases 
[7]. The objective of this study was to estimate the rates of first 
documented occurrence of HTN, DM, and CKD, by age, sex, 
and race, among ART-experienced adults living with HIV.
METHODS
Study Population
We analyzed data from the North American AIDS Cohort 
Collaboration on Research and Design (NA-ACCORD), a 
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collaboration of single-site and multisite U.S. and Canadian 
cohorts of HIV-infected adults that has been described previ-
ously [8]. In brief, cohort participants eligible for inclusion in 
NA-ACCORD were required to have at least 2 HIV care visits 
within 12 months. Each cohort has standardized methods of 
data collection and submits data on enrolled participant char-
acteristics, diagnoses, laboratory measures, prescribed medica-
tions, and vital status to the Data Management Core (University 
of Washington, Seattle). The completeness and accuracy of 
data are evaluated before data elements are harmonized across 
cohorts. Data are then sent to the Epidemiology/Biostatistics 
Core (Johns Hopkins University, Baltimore, Maryland), where 
additional quality control procedures are executed and analytic 
files are created.
For this analysis, clinical cohorts were included if data ele-
ments to ascertain HTN, DM, and CKD were readily availa-
ble. There were 16 cohorts that contributed data for HTN, 20 
cohorts for DM, and 22 cohorts for CKD. Because our inter-
est was in an ART-treated population, as these individuals are 
most likely to age with HIV and be susceptible to these NCDs, 
the study population was restricted to participants who were 
ART-experienced and contributed data at least twice between 
1 January 2000 and 31 December 2013 (see Supplementary 
Figure 1 for more details on inclusion criteria).
Outcomes: Type 2 Diabetes Mellitus, Chronic Kidney Disease, and Treated 
Hypertension
The outcomes of interest were the first documented occurrence 
of DM, CKD, and HTN during the study period. Any DM was 
defined as having either a glycosylated hemoglobin (HgbA1c) 
level of ≥6.5%; documented use of a diabetes-specific medi-
cation; or documented use of a diabetes-related medication in 
addition to a diagnosis of diabetes. CKD was laboratory-based, 
defined as 2 values of estimated glomerular filtration rate (eGFR) 
<60 mL/minute/1.73 m2 (>90 days apart without an intervening 
normal value) and calculated by the CKD-EPI (Chronic Kidney 
Disease Epidemiology Collaboration) equation [9]. HTN was 
defined as ever having a diagnosis of hypertension in conjunc-
tion with documented use of antihypertensive medication, thus 
capturing treated hypertension.
We attempted to account for detection bias by excluding 
prevalent cases defined as evidence of these outcomes prior to, 
at, or within 9 months after study entry. For our CKD analysis, 
to account for a bias in the rate of CKD progression between 
individuals entering the study with low vs high renal function, 
participants were required to have an eGFR >90  mL/min-
ute/1.73 m2 within 6 months prior to or after they began con-
tributing person-time to the analysis.
Covariates
Sex, race (“black” for those reporting black or black Hispanic, 
and “non-black” otherwise, due to the small number of events 
that occur within more granular racial strata), and injection 
drug use as a risk factor for HIV transmission (categorized as 
self-reported injection drug use, or injection drug use and men 
who have sex with men) were reported at enrollment into the 
NA-ACCORD. For our study, HIV transmission risk group 
was collapsed by injection drug use status because of previous 
evidence to suggest that injection drug users (IDUs) are more 
disadvantaged in terms of health, receiving less than optimal 
healthcare compared to other HIV subpopulations [10].
Smoking status was assigned based on all self-reported and 
medical record data contributed to NA-ACCORD. Any indi-
viduals who reported using tobacco or had a clinician-doc-
umented diagnosis of smoking were designated as smokers, 
individuals with no evidence of smoking were categorized as 
nonsmokers, and individuals with a missing report or diagno-
sis were deemed missing. Body mass index (BMI), calculated as 
(kg) / [height (m)]2, was obtained no more than 6 months prior 
to when a participant began contributing data to the analysis. 
Calendar year at ART initiation was categorized as 1996–1999, 
2000–2005, or 2006–2013. ART prescription was defined con-
sistent with US guidelines as a regimen of ≥3 antiretroviral 
agents from at least 2 classes or a triple nucleoside/nucleotide 
reverse transcriptase inhibitor regimen containing abacavir or 
tenofovir [11]. A  history of an AIDS diagnosis at entry into 
our study was defined according to 1993 criteria from the 
Centers for Disease Control and Prevention, excluding the 
CD4 T-lymphocyte count (CD4) <200 cells/µL criterion to 
avoid collinearity when adjusting for time-varying CD4 in our 
analysis [12].
CD4 was categorized as <200, 200–349, 350–499, and ≥500 
cells/µL. A combined time-varying measure of viral suppression 
(HIV RNA value ≤400 copies/mL) and ART use was created 
due to the collinearity of these variables, and was categorized 
as (1) ART-experienced but not currently prescribed ART, (2) 
currently prescribed ART but not virally suppressed, and (3) 
currently prescribed ART and virally suppressed.
Statistical Analyses
Differences in demographic and clinical characteristics were 
explored with Pearson χ2 tests for categorical variables.
We calculated incidence rates (IRs) per 100 person-years 
(PY) and 95% confidence intervals (CIs) for each disease out-
come. To examine the association between sex–race subgroup 
(non-black women, black women, non-black men, and black 
men) and NCDs, crude and adjusted incidence rate ratios (IRRs 
and aIRRs, respectively) and 95% CIs were estimated using 
Poisson regression models. The person-time contributed by an 
individual under observation for the outcome of interest was 
accrued from study entry, defined as the later date of either ART 
initiation or 1 January 2000. Participants were followed until 
the outcome of interest, death, 1 year after the last CD4 or HIV 
RNA measure, 70 years of age, or 31 December 2013, whichever 
came first. We censored person-time at and beyond age 70 to 
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avoid skewed disease rates and cumulative incidence estimates 
as these individuals had small risk set sample sizes.
Cumulative incidence estimates as of age 70 were obtained 
for each disease outcome accounting for the competing risk of 
death [13]. We report our findings using age as the time met-
ric to compare people of similar age, thus having the greatest 
possible control for age as a confounder [14]. In a supplement, 
we present our data using a scale that is comparable with other 
studies (time metric = time on study) [15–19]. The proportional 
subdistribution hazard assumption was assessed by including 
an interaction term between age and sex–race in our compet-
ing risk regression model. Finally, to account for confounding 
by BMI, we conducted a subgroup analysis restricting to those 
with BMI measurements.
Analyses were performed using SAS software version 9.4 
(SAS Institute, Cary, North Carolina) and Stata software version 
12.1 (StataCorp, College Station, Texas). All statistical tests were 
2-sided and a P value < .05 guided statistical interpretation.
RESULTS
Study Population Characteristics
For each analysis, the majority of the study population was 
<50 years of age at study entry, male, non-black, did not report 
injection drug use, had not experienced AIDS, had a recent 
CD4 of <200 cells/µL, and was on ART but not virally sup-
pressed (Table 1). Among participants with BMI measured at 
study entry, less than a fifth were overweight or obese for the 
HTN and DM analysis, but almost half were overweight or 
obese in the CKD analysis. Participants who developed any one 
of the NCDs during the study period differed by demographic 
and clinical characteristics at study entry compared with per-
sons who remained event-free. Older age, black race, injection 
drug use, a history of smoking, and having initiated ART in ear-
lier calendar periods were each associated with increased rates 
of first occurrence of HTN, DM, and CKD (Table 2).
Overall, rates of first occurrence for each disease were as 
follows: 2.6/100 PY for HTN (n  =  9547 events; n  =  4198 for 
non-Hispanic whites, n  =  4711 for non-Hispanic blacks, 
n  =  487 for Hispanics, and n  =  151 for other), 1.2/100 PY 
for DM (n = 5881 events; n = 2275 for non-Hispanic whites, 
n  =  2988 for non-Hispanic blacks, n  =  498 for Hispanics, 
n = 120 for other), and 0.6/100 PY for CKD (n = 1785 events; 
n  =  742 for non-Hispanic whites, n  =  901 for non-Hispanic 
blacks, n = 100 for Hispanics, n = 42 for others). The median 
follow-up time for each analysis was 4.4 (interquartile range 
[IQR], 2.1–7.8) years, 4.8 (IQR, 2.8–8.0) years, and 5.0 (IQR, 
2.5–8.5) years, respectively. Median age at diagnosis for HTN, 
DM, and CKD for the observed cases was 48 (IQR, 43–54), 49 
(IQR, 43–55), and 51 (IQR, 45–57) years, respectively. Median 
follow-up for those with and without HTN was 3.6 (IQR, 2.0–
6.2) and 4.6 (IQR,  2.2–8.1) years, respectively; for those with 
and without DM was 3.3 (IQR, 1.5–6.0) and 5.0 (IQR, 2.4–8.1) 
years, respectively; and for those with and without CKD was 5.3 
(IQR, 3.2–8.0) and 5.1 (IQR, 2.5–8.5) years, respectively.
Estimation of Outcomes by Subgroup of Sex and Race
We observed disparities by sex and race after adjusting for age, 
risk behavior, and HIV-related factors in our Poisson analyses. 
Regardless of sex, black race was significantly associated with 
higher rates of HTN (relative to non-black men: aIRR, 1.8 [95% 
CI, 1.6–2.1] for black women and 1.5 [95% CI, 1.4–1.7] for 
black men). For DM, black men, black women, and non-black 
women experienced significantly higher rates of DM relative 
to non-black men (aIRRs, 1.4 [95% CI, 1.2–1.6], 2.0 [95% CI, 
1.6–2.3], and  1.4 [95% CI, 1.2–1.7], respectively). Last, black 
and non-black women had significantly higher CKD rates com-
pared with non-black men (aIRRs, 1.5 [95% CI, 1.2–1.9] and 
1.5 [95% CI, 1.1–2.0], respectively). Study entry characteristics 
by sex–race subgroup are presented in Supplementary Table 1.
We also assessed whether the relationship between age 
and NCD was significantly different by sex–race subgroup 
(Figure  1). Adjusted rates of NCD occurrence increased with 
older age for each sex–race subgroup (Table 3), and was signif-
icantly different between sex–race subgroups for HTN and DM 
(all P ≤ .02).
Evidence for disparities in the cumulative incidences between 
sex–race group was observed. Using age as the time metric, 
cumulative incidence estimates between sex–race groups for 
HTN by age 70 ranged from 51% to 73% (Figure  2A), from 
34% to 52% for DM (Figure  2B), and from 25% to 38% for 
CKD (Figure  2C). As an example of interpreting an estimate 
from Figure 2A, among black men who have reached the age 
of 55, the probability of experiencing HTN is 51%, conditional 
on their surviving free of HTN up until that age. Disparities 
between groups of sex–race were also observed when using time 
on study as the time metric (results not shown; Supplementary 
Figure  2). The proportional hazards assumption was met (all 
P ≥ .9).
Given the potential influence of BMI on NCD development, 
we conducted a subanalysis for the minority of participants for 
whom BMI data were available at study entry (n = 21 615 for 
HTN, n = 28 963 for DM, n = 18 996 for CKD). Sex–race dis-
parities persisted after adjusting for BMI (results not shown).
DISCUSSION
Sex–race disparities in the occurrence of HTN, DM, and CKD 
persisted among men and women aging with HIV with access 
to care. As ART-treated adults age with HIV, it becomes increas-
ingly important to describe NCD epidemiology [20]. Estimating 
the occurrence of HTN, DM, and CKD by specific sex–race sub-
groups of adults aging with HIV further develops the evidence of 
the persistent racial disparity as shown in other studies of inci-
dence by age, sex, or race [15, 17, 18, 20, 21]. In our study, black 
adults experienced at least a 1.4-fold higher rate of HTN, DM, and 
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CKD compared with non-black adults. Our findings are a call to 
action to (1) better understand the drivers of these disparities that 
persist in an environment with equal access to care in attempts to 
meet the Healthy People 2020 goals and (2) fill the gaps in NCD 
prevention services among adults aging with HIV [22].
Our study population experienced lower rates of HTN and 
CKD, and rates of DM within range of those reported in other 
HIV-infected populations. In previous literature, HTN, DM, 
and CKD rates have been reported to range from 3.44 to 22/100 
PY, from 0.31 to 2.6/100 PY, and from 0.88 to 1.12/100 PY, 
respectively; among HIV-uninfected individuals, ranges were 
0.59–9.11/100 PY, 0.62–0.71/100 PY, and 1.04–4.46/100 PY, 
respectively [15–21, 23–28]. Heterogeneity in measurement 
of the outcomes is partially responsible for the large ranges 
Table 1. Characteristics of Antiretroviral Therapy–Experienced, HIV-Infected Adults at Study Entry During 2000–2013
HTN 
(n = 9547)
No HTN 
(n = 58 858)
DM 
(n = 5881)
No DM 
(n = 80 908)
CKD 
(n = 1785)
No CKD 
(n = 50 626)
Variable PY = 41 291 PY = 323 788 PY = 23 918 PY = 452 258 PY = 10 053 PY = 288 382
Age, y
 <40 2734 29 27 002 46 1488 25 33 831 42 430 24 24 012 47
 40–49 4201 44 21 555 37 2530 43 30 270 37 782 44 18 553 37
 50–59 2234 23 8673 15 1601 27 13 789 17 480 27 7044 14
 60–69 378 4 1628 3 262 4 3018 4 93 5 1017 2
Sex
 Male 8464 89 48 908 83 4842 82 67 621 84 1481 83 42 200 83
Race
 Non-black 4836 51 35 330 60 2893 49 47 838 59 884 50 28 592 56
 Black 4711 49 23 528 40 2988 51 33 070 41 901 50 22 034 44
Injection drug use as HIV transmission risk
 No 6829 72 47 617 81 4230 72 63 921 79 1191 67 39 948 79
Smokinga
 Never 717 8 5927 10 397 7 9153 11 146 8 5653 11
 Ever 2615 27 20 798 35 1565 27 30 142 37 646 36 19 692 39
 Missing 6215 65 32 133 55 3919 67 41 613 51 993 56 25 281 50
BMI, kg/m2
 <18.5 913 10 10 268 17 429 7 14 001 17 28 2 727 1
 18.5–24.9 685 7 5961 10 408 7 8688 11 284 16 9293 18
 25–29.9 334 3 2184 4 353 6 3401 4 150 8 5655 11
 30–40 58 1 304 1 73 1 473 1 55 3 2391 5
 >40 57 1 851 1 35 1 1102 1 12 1 401 1
 Missing 7500 79 39 290 67 4583 78 53 243 66 1256 70 32 159 64
AIDS
 No 7811 82 47 252 80 4668 79 65 016 80 1341 75 40 770 81
Calendar period of ART initiation
 1996–1999 4651 49 17 707 30 2804 48 25 534 32 851 48 14 895 29
 2000–2005 3669 38 21 231 36 2361 40 29 892 37 766 43 19 204 38
 2006–2013 1101 12 17 595 30 638 11 22 624 28 138 8 14 962 30
CD4 count, cells/µL
 >500 1684 18 10 208 17 1257 21 14 474 18 284 16 9345 18
 350–499 1219 13 8223 14 852 14 11 790 15 197 11 7701 15
 200–349 1772 19 11 964 20 1021 17 17 167 21 351 20 11 118 22
 <200 4870 51 28 458 48 2751 47 37 471 46 953 53 22 459 44
ART and HIV RNA, copies/mL
 ≤400, on ART 2848 30 16 091 27 1933 33 23 031 28 439 25 14 279 28
 >400, on ART 3620 38 26 026 44 2202 37 35 650 44 853 48 24 334 48
 Off ART 207 2 1235 2 187 3 1936 2 60 3 1120 2
 Missing 2872 30 15 506 26 1559 27 20 291 25 433 24 10 893 22
Data are presented as No. (%) unless otherwise indicated. Statistical differences were assessed comparing cases to noncases for each NCD. All covariates were statistically significant 
(P < .05) with the exception of sex and BMI for the CKD analysis.
Abbreviations: ART, antiretroviral therapy; BMI, body mass index; CKD, chronic kidney disease; DM, diabetes mellitus; HIV, human immunodeficiency virus; HTN, hypertension;   
NCD, noncommunicable diseases; PY, person-years.
a Smoking data in NA-ACCORD included observed and imputed observations. Across all 3 study populations, 3% of participants were imputed to be never smokers, 10% were imputed 
to be ever smokers, 7%–8% were observed as never smokers, 24%–29% were observed as ever smokers, and 50%–56% had missing smoking data. Results of our analyses pooled 
smoking coefficients across 5 datasets with imputed smoking status, and we obtained valid inferences by accounting for associated covariance matrices between imputed datasets.
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Table 2. Noncommunicable Disease Rates (per 100 person-years) Among Antiretroviral Therapy–Experienced, HIV-Infected Adults, 2000–2013
Treated Hypertension (n = 68 405) Type 2 Diabetes (n = 86 789) Chronic Kidney Disease (n = 52 411)
Variable Events PY IR (95% CI) Events PY IR (95% CI) Events PY IR (95% CI)
Age, y
 <40 1388 109 425 1.3 (1.2–1.3) 806 130 208 0.6 (.6–.7) 167 92 767 0.2 (.2–.2)
 40–49 3804 148 131 2.6 (2.5–2.7) 2232 190 276 1.2 (1.1–1.2) 605 122 913 0.5 (.5–.5)
 50–59 3407 87 322 3.9 (3.8–4.0) 2190 124 127 1.8 (1.7–1.8) 694 68 786 1.0 (.9–1.1)
 60–69 948 20 202 4.7 (4.4–5.0) 653 31 565 2.1 (1.9–2.2) 319 13 968 2.3 (2.0–2.5)
Sex
 Male 8464 310 127 2.7 (2.7–2.8) 4842 399 860 1.2 (1.2–1.2) 1481 248 835 0.6 (.6–.6)
 Female 1083 54 953 2.0 (1.9–2.1) 1039 76 315 1.4 (1.3–1.4) 304 49 599 0.6 (.6–.7)
Race
 Non-black 4836 220 407 2.2 (2.1–2.3) 2893 283 628 1.0 (1.0–1.1) 884 169 906 0.5 (.5–.6)
 Black 4711 144 672 3.3 (3.2–3.4) 2988 192 547 1.6 (1.5–1.6) 901 128 529 0.7 (.7–.8)
Injection drug use as HIV transmission risk
 No 6829 287 518 2.4 (2.3–2.4) 4230 370 127 1.1 (1.1–1.2) 1191 230 247 0.5 (.5–.6)
 Yes 2718 77 562 3.5 (3.4–3.6) 1651 106 048 1.6 (1.5–1.6) 594 68 187 0.9 (.9–.9)
Smoking
 Never 729 41 021 1.8 (1.7–1.9) 297 57 707 0.7 (.6–.8) 146 35 927 0.4 (.4–.5)
 Ever 2636 125 111 2.1 (2.0–2.2) 1565 179 512 0.9 (.8–.9) 646 119 984 0.5 (.5–.6)
 Missing 6365 212 274 3.0 (2.9–3.1) 3919 238 956 1.6 (1.6–1.7) 993 142 524 0.7 (.7–.7)
BMI at entry, kg/m2
 <18.5 913 60 520 1.5 (1.4–1.6) 429 82 159 0.5 (.5–.6) 28 3834 0.7 (.5–1.1)
 18.5–24.9 685 34 790 2.0 (1.8–2.1) 408 51 176 0.8 (.7–.9) 284 55 107 0.5 (.5–.6)
 25–29.9 334 11 874 2.8 (2.5–3.1) 353 19 503 1.8 (1.6–2.0) 150 33 341 0.5 (.4–.5)
 30–40 58 1533 3.8 (2.9–4.9) 73 2673 2.7 (2.2–3.4) 55 13 568 0.4 (.3–.5)
 >40 57 4314 1.3 (1.0–1.7) 35 5606 0.6 (.4–.9) 12 2338 0.5 (.3–.9)
 Missing 7500 252 049 3.0 (2.9–3.0) 4583 315 057 1.5 (1.4–1.5) 1256 190 246 0.7 (.6–.7)
AIDS at entry
 No 7811 298 095 2.6 (2.6–2.7) 4668 383 941 1.2 (1.2–1.3) 1341 240 786 0.6 (.5–.6)
 Yes 1736 66 984 2.6 (2.5–2.7) 1213 92 234 1.3 (1.2–1.4) 444 57 648 0.8 (.7–.9)
Calendar year at ART initiation
 2006–2013 1101 67 973 1.6 (1.5–1.7) 638 80 535 0.8 (.7–.9) 138 53 031 0.3 (.2–.3)
 2000–2005 3669 141 696 2.6 (2.5–2.7) 2361 189 319 1.3 (1.2–1.3) 766 123 619 0.6 (.6–.7)
 1996–1999 4651 146 738 3.2 (3.1–3.3) 2804 195 250 1.4 (1.4–1.5) 851 116 228 0.7 (.7–.8)
ART and HIV RNA, copies/mL
 ≤400, on ART 5493 183 209 3.0 (2.9–3.1) 3387 251 583 1.4 (1.3–1.4) 1034 162 144 0.6 (.6–.7)
 >400, on ART 1487 46 523 3.2 (3.0–3.4) 925 61 277 1.5 (1.4–1.6) 320 39 789 0.8 (.7–.9)
 Off ART 2447 131 500 1.9 (1.8–1.9) 467 34 259 1.4 (1.2–1.5) 152 21 030 0.7 (.6–.8)
 Missing 120 3847 3.1 (2.6–3.7) 1102 129 056 0.9 (.8–.9) 279 75 472 0.3 (.3–.4)
Abbreviations: ART, antiretroviral therapy; BMI, body mass index; CI, confidence interval; HIV, human immunodeficiency virus; IR, incidence rates per 100 person-years; PY, person-years.
Figure 1. Unadjusted rates of first occurring treated hypertension (A), type 2 diabetes mellitus (B), and chronic kidney disease (C), stratified by sex and race group. Vertical 
bars represent 95% confidence intervals for rates. Abbreviation: PY, person-years.
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Table 3. Crude and Adjusted Incidence Rate Ratios for Noncommunicable 
Diseases Among Antiretroviral Therapy–Experienced, HIV-Infected Adults 
by Age, Sex, and Race, 2000–2013
Age Group, y
Univariate Analysis Multivariable Analysisa
IRR (95% CI) aIRR (95% CI)
Hypertension (n = 68 405)
 Non-black women
  <40 1 Ref 1 Ref
  40–49 1.7 (1.3–2.3) 1.6 (1.2–2.2)
  50–59 2.8 (2.1–3.7) 2.5 (1.7–3.5)
  60–69 2.9 (1.8–4.6) 2.2 (1.2–4.1)
 Black women
  <40 1 Ref 1 Ref
  40–49 2.0 (1.7–2.3) 1.6 (1.3–1.9)
  50–59 2.4 (1.9–2.9) 1.6 (1.2–2.2)
  60–69 1.6 (1.0–2.7) 1.1 (.5–2.5)
 Non-black men
  <40 1 Ref 1 Ref
  40–49 2.0 (1.9–2.2) 1.9 (1.7–2.2)
  50–59 3.2 (2.9–3.5) 2.5 (2.2–2.9)
  60–69 4.1 (3.7–4.6) 3.0 (2.4–3.8)
 Black men
  <40 1 Ref 1 Ref
  40–49 2.0 (1.8–2.2) 1.8 (1.5–2.1)
  50–59 2.9 (2.6–3.2) 2.4 (1.9–2.9)
  60–69 3.6 (3.1–4.1) 2.4 (1.0–1.4)
Type 2 diabetes (n = 86 789)
 Non-black women
  <40 1 Ref 1 Ref
  40–49 1.8 (1.4–2.4) 1.4 (.9–2.1)
  50–59 2.4 (1.8–3.3) 2.4 (1.5–3.7)
  60–69 2.5 (1.6–4.0) 1.9 (1.0–3.9)
 Black women
  <40 1 Ref 1 Ref
  40–49 1.7 (1.4–2.0) 1.5 (1.1–2.1)
  50–59 2.1 (1.8–2.6) 1.6 (1.1–2.3)
  60–69 2.7 (1.9–3.8) 2.8 (1.7–4.8)
 Non-black men
  <40 1 Ref 1 Ref
  40–49 2.2 (1.9–2.5) 2.0 (1.6–2.5)
  50–59 3.7 (3.2–4.2) 3.4 (2.7–4.3)
  60–69 4.6 (3.9–5.3) 4.7 (3.5–6.2)
 Black men
  <40 1 Ref 1 Ref
  40–49 1.9 (1.7–2.2) 1.3 (1.0–1.8)
  50–59 2.7 (2.3–3.1) 1.8 (1.3–2.5)
  60–69 3.1 (2.6–3.7) 2.8 (1.9–4.2)
Chronic kidney disease (n = 52 411)
 Non-black women
  <40 1 Ref 1 Ref
  40–49 3.2 (1.9–5.6) 2.7 (1.3–5.6)
  50–59 4.5 (2.4–8.3) 3.9 (1.7–8.9)
  60–69 14.3 (7.4–27.8) 16.7 (6.9–40)
 Black women
  <40 1 Ref 1 Ref
  40–49 2.5 (1.7–3.6) 1.7 (1.0–2.8)
  50–59 4.3 (2.9–6.4) 3.6 (2.1–6.2)
  60–69 7.0 (3.9–12.5) 8.1 (3.9–16.6)
Age Group, y
Univariate Analysis Multivariable Analysisa
IRR (95% CI) aIRR (95% CI)
 Non-black men
  <40 1 Ref 1 Ref
  40–49 4.1 (3.0–5.5) 3.7 (2.4–5.5)
  50–59 8.4 (6.2–11.4) 7.3 (4.8–11.1)
  60–69 22.1 (16.1–30.4) 16.8 (10.4–26.9)
 Black men
  <40 1 Ref 1 Ref
  40–49 2.0 (1.5–2.7) 1.6 (1.0–2.6)
  50–59 4.5 (3.4–5.9) 4.0 (2.5–6.6)
  60–69 8.8 (6.4–12.0) 9.6 (5.2–17.5)
Confidence intervals that do not overlap 1 are shown in bold. 
Abbreviations: aIRR, adjusted incidence rate ratio; CI, confidence interval; IRR, incidence 
rate ratio; Ref = reference.
a Adjusted Poisson analyses controlled for injection drug use, history of smoking, calendar 
year at antiretroviral therapy (ART) initiation, cohort, AIDS at entry, time-updated CD4 
count, and the combined variable for ART and viremia status (where viral suppression 
≤400 copies/mL).
Table 3. Continued
of incidence estimates. We focused on treated HTN and did 
not include fasting glucose measures in our DM definition. 
Additionally, high eGFRs at study entry restricted the rate of 
decline.
Given our broad study period, temporal changes in the effec-
tiveness, tolerability profiles, and convenience of ART regimens 
may play an important role in our observed outcome rates. In 
our population, a high proportion of individuals was prescribed 
ART but not virally suppressed at study entry. However, this 
was a function of our study entry definition, which allowed 
the inclusion of a heterogeneous population of individuals: (1) 
those initiating ART and who thus have unsuppressed viral load 
at initiation, and (2) those who may have been exposed to ear-
lier ART formulations. Earlier ART regimens may predispose 
individuals to NCD development compared with contemporary 
regimens [11], underscoring the continued importance of mon-
itoring HTN, DM, and CKD [28]. For this reason, in our study 
it is possible that rates of NCD occurrence were higher in ear-
lier years, but declined following the introduction and uptake of 
newer ARTs. Potential differences in ART availability by calen-
dar period, and therefore differences in risk of NCD occurrence 
due to type of ART exposure, were adjusted for in our analyses 
by controlling for era of ART initiation.
As observed in other studies, the rates of NCDs were fre-
quently higher among black compared with non-black persons 
[16, 18, 29]. Despite blacks comprising only 12% of the US 
population, blacks have a disproportionate burden of HIV with 
infection rates 8 times higher than those of whites [30]. The 
confluence of this disproportionate burden of HIV infection 
and the associations of race with NCDs indicates an important 
clinical and public health issue. The already complex clinical 
management of HIV infection [31], and evidence supporting 
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that disease preventive services are less common among dis-
advantaged communities [32], suggest a need for primary and 
secondary disease prevention strategies directed at minorities.
Consistent with accumulating evidence identifying women 
at greater risk for several adverse health outcomes compared 
with men [7], women in our study experienced higher rates of 
DM and CKD. In the setting of HIV infection, reasons for sex 
disparities are likely multifactorial, and may include biological 
differences [33] and differences in care retention [34]. In light 
of this, women aging with HIV may require approaches to care 
that are distinct from those routinely used for men in terms of 
devising effective prevention and treatment plans for NCDs.
The foreseeable growth of NCDs among HIV-infected indi-
viduals will have implications for clinical care and healthcare 
resources [20]. As HIV-infected individuals age, an increas-
ing number of treatable NCDs may give rise to issues related 
to polypharmacy, with management of both ARTs and treat-
ment of NCDs [35]. To date, there is a dearth of guidelines on 
how best to clinically manage older individuals with multiple 
diseases [36], and it is unclear whether undertaking earlier or 
intensified screening for specific age-related diseases is justi-
fiable [37]. Appropriate healthcare delivery models that are 
diverse in medical expertise will be fundamental to the care of 
HIV-infected persons.
Our results should be interpreted in acknowledgement of 
their limitations. As our study population excludes persons who 
did not successfully access HIV care, our findings that HTN, 
DM, and CKD are more likely to be diagnosed among blacks 
may reflect an underestimate of true disparity, reinforcing the 
urgency of linking minorities to care [38]. We may have under-
estimated HTN and CKD events by excluding individuals with 
untreated hypertension, and excluding individuals who may 
have progressed to CKD more rapidly by requiring an eGFR 
>90  mL/minute/1.73  m2 at study entry, respectively. It is also 
feasible that NCD rates are higher among individuals being 
followed for care for longer periods of time. But we contend 
that it is important to describe what is being seen in clinical 
settings as individuals seek care. The extent of missing data on 
BMI is another limitation. However, our subanalyses confirmed 
the persistence of the sex–race disparity after adjusting for BMI. 
Given previous evidence to suggest that BMI after ART initia-
tion is relatively stable [39], adjusting for BMI in a time-varying 
manner may not add more than what we have shown. Given 
that our goal was to quantify rates of first occurrence for HTN, 
DM, and CKD, the analysis for each outcome was independ-
ent and we reported results that did not adjust for concomi-
tant disease. Finally, although an HIV-uninfected comparison 
group would have provided estimates as to the role of HIV in 
Figure 2. Cumulative incidence curves for treated hypertension (A), type 2 diabetes mellitus (B), and chronic kidney disease (C), stratified by sex and race. Abbreviations: 
BM, black men; BW, black women; NBM, non-black men; NBW, non-black women.
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the disparities shown, the objective was not to examine the HIV 
effect, but rather to describe the epidemiology of NCDs among 
individuals with access to HIV clinical care.
In summary, we found increased rates of HTN, DM, and 
CKD, especially among HIV-infected black men and women. 
Minimizing sex–race health disparities through more proactive 
preventive care, such as smoking cessation, physical activity, 
and nutritional assistance programs, will shape the quality of 
extended life made possible by effective ART in this population 
engaged in medical care. Understanding North American rates 
of NCDs in HIV-infected persons, and sex–race disparities in 
NCD occurrence, is a necessary step for responding to the U.S. 
National HIV/AIDS Strategy’s call to improve long-term health 
outcomes among HIV-infected individuals and to prepare for 
the clinical and public health challenges that may lie ahead [38].
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